Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Por um escritor misterioso
Descrição
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial - The Lancet
VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma
Cancers, Free Full-Text
Cancers, Free Full-Text
Increasing cure rates of solid tumors by immune checkpoint inhibitors, Experimental Hematology & Oncology
Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Episode 1: The Role of Adjuvant and Neoadjuvant Therapy in Melanoma
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology
Adjuvant and Neoadjuvant Therapy in Melanoma - Rodabe N. Amaria, MD
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Neoadjuvant or adjuvant immunotherapy in melanoma stage iii
de
por adulto (o preço varia de acordo com o tamanho do grupo)
